Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Cash from Financing Activities (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Cash from Financing Activities for 6 consecutive years, with $5000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 82.76% to $5000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19000.0 through Dec 2025, down 82.41% year-over-year, with the annual reading at $19000.0 for FY2025, 82.41% down from the prior year.
  • Cash from Financing Activities hit $5000.0 in Q4 2025 for Bolt Biotherapeutics, down from $14000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $297.0 million in Q1 2021 to a low of $5000.0 in Q4 2025.
  • Historically, Cash from Financing Activities has averaged $26.0 million across 5 years, with a median of $125500.0 in 2022.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 873485.29% in 2021 and later tumbled 99.96% in 2022.
  • Year by year, Cash from Financing Activities stood at $495000.0 in 2021, then crashed by 70.91% to $144000.0 in 2022, then decreased by 26.39% to $106000.0 in 2023, then plummeted by 72.64% to $29000.0 in 2024, then tumbled by 82.76% to $5000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for BOLT at $5000.0 in Q4 2025, $14000.0 in Q2 2025, and $29000.0 in Q4 2024.